Hemispherx Biopharma Publishes New Data on Ampligen(R)'s Activity in Chronic Fatigue Syndrome (CFS)

GLOBE NEWSWIRE -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), announced the publication of a peer-reviewed article providing new data on Ampligen® [rintatolimod; poly(I)·poly(C12,U)], an experimental therapeutic in Phase III clinical testing, in the current issue of The Journal of Applied Research.